{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:25:53Z","timestamp":1761895553762},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/ppo.0b013e31826aed4f","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T21:40:28Z","timestamp":1348263628000},"page":"390-395","source":"Crossref","is-referenced-by-count":12,"title":["Has Single-Agent Rituximab Replaced Watch-and-Wait for a Patient With Asymptomatic Low-Grade Follicular Lymphoma?"],"prefix":"10.1097","volume":"18","author":[{"given":"Lisa","family":"Lowry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-90-1-10","article-title":"No initial therapy for stage III and IV non-Hodgkins lymphomas of favorable histologic types.","volume":"90","author":"Portlock","year":"1979","journal-title":"Ann Intern Med"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkins lymphomas.","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"R3-3-20210203","first-page":"651","article-title":". The natural history of low grade non-Hodgkins lymphoma and the impact of a no initial treatment policy on survival.","volume":"80","author":"OBrien","year":"1991","journal-title":"QJM"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":". Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe dEtude des Lymphomes Folliculaires. Groupe dEtude des Lymphomes de lAdulte.","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":". Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":". New treatment options have changed the survival of patients with follicular lymphoma.","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":". Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center.","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":". Meta-analysis to evaluate the role of interferon in follicular lymphoma.","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":". Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group.","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":". Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":". Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy and molecular evaluation for patients with follicular lymphoma with a low tumor burden: clinical.","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":". Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 3598.","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":". Follicular lymphoma in the United States: first report of the national LymphoCare study.","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":". Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":". Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","article-title":". Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":". Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":". Population-based analysis of incidence and outcome of transformed non-Hodgkins lymphoma.","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":". Incidence, risk factors and outcome of histological transformation in follicular lymphoma.","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":". Long-term survival after histologic transformation of low-grade follicular lymphoma.","volume":"13","author":"Yuen","year":"1995","journal-title":"J Clin Oncol"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":". Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":". Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":". Follicular lymphoma International Prognostic Index.","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":". Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0b013e31826aed4f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:26:41Z","timestamp":1620970001000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201209000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31826aed4f","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}